Innocrin Pharmaceuticals
Innocrin Pharmaceuticals, Inc., a US-based company, develops oral inhibitors for prostate cancer treatment.
Founded
2014Innocrin Pharmaceuticals, Inc., a US-based company, develops oral inhibitors for prostate cancer treatment.
Innocrin Pharmaceuticals, Inc., founded in Durham, United States, is dedicated to the discovery and development of oral inhibitors for the treatment of castration-resistant prostate cancer. The company's core mission is to provide innovative therapeutic solutions for patients suffering from advanced prostate cancer. By focusing on the development of next-generation endocrine therapies, Innocrin aims to address unmet medical needs and improve patient outcomes in the oncology sector.
Notable figures associated with Innocrin Pharmaceuticals include key researchers and industry experts who have significantly contributed to the field of oncology. The company has garnered attention from prominent investors in the pharmaceutical industry, reflecting confidence in its innovative approach. Innocrin's achievements include advancing its lead drug candidates through clinical trials, demonstrating promising efficacy and safety profiles. The overall impact of Innocrin Pharmaceuticals lies in its potential to transform prostate cancer treatment and offer new hope to patients worldwide.
Companies similar to Innocrin Pharmaceuticals include Crinetics Pharmaceuticals, Lipocine, Core Oncology and Izun Pharmaceuticals.
Innocrin Pharmaceuticals was founded in 2014.
Innocrin Pharmaceuticals' headquarters is located in Durham, NC, US.
Innocrin Pharmaceuticals' most recent funding round was for $28M (USD) in April 2015.
As of Apr 14, 2015, Innocrin Pharmaceuticals has disclosed funding of $36M (USD). Undisclosed round amounts are excluded.
Innocrin Pharmaceuticals has 11 employees as of Feb 5, 2024.
Izun Pharmaceuticals
izunpharma.com
